429 related articles for article (PubMed ID: 12589476)
1. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR
Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476
[TBL] [Abstract][Full Text] [Related]
2. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
[TBL] [Abstract][Full Text] [Related]
3. 11C-acetate PET imaging of prostate cancer.
Oyama N; Akino H; Kanamaru H; Suzuki Y; Muramoto S; Yonekura Y; Sadato N; Yamamoto K; Okada K
J Nucl Med; 2002 Feb; 43(2):181-6. PubMed ID: 11850482
[TBL] [Abstract][Full Text] [Related]
4. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
6. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.
Vees H; Buchegger F; Albrecht S; Khan H; Husarik D; Zaidi H; Soloviev D; Hany TF; Miralbell R
BJU Int; 2007 Jun; 99(6):1415-20. PubMed ID: 17428249
[TBL] [Abstract][Full Text] [Related]
7. Malignant lipogenesis defined by
Regula N; Häggman M; Johansson S; Sörensen J
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2131-2138. PubMed ID: 27392615
[TBL] [Abstract][Full Text] [Related]
8. Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer.
Chang CH; Wu HC; Tsai JJ; Shen YY; Changlai SP; Kao A
Urol Int; 2003; 70(4):311-5. PubMed ID: 12740497
[TBL] [Abstract][Full Text] [Related]
9. Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence.
Spick C; Polanec SH; Mitterhauser M; Wadsak W; Anner P; Reiterits B; Haug AR; Hacker M; Beheshti M; Karanikas G
Anticancer Res; 2015 Dec; 35(12):6787-91. PubMed ID: 26637897
[TBL] [Abstract][Full Text] [Related]
10. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
11. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
12. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer.
Kotzerke J; Volkmer BG; Neumaier B; Gschwend JE; Hautmann RE; Reske SN
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1380-4. PubMed ID: 12271422
[TBL] [Abstract][Full Text] [Related]
13. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
14. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy.
Schöder H; Herrmann K; Gönen M; Hricak H; Eberhard S; Scardino P; Scher HI; Larson SM
Clin Cancer Res; 2005 Jul; 11(13):4761-9. PubMed ID: 16000572
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
16. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.
Yu EY; Muzi M; Hackenbracht JA; Rezvani BB; Link JM; Montgomery RB; Higano CS; Eary JF; Mankoff DA
Clin Nucl Med; 2011 Mar; 36(3):192-8. PubMed ID: 21285676
[TBL] [Abstract][Full Text] [Related]
17. [18F]FDG imaging of head and neck tumours: comparison of hybrid PET and morphological methods.
Dresel S; Grammerstorff J; Schwenzer K; Brinkbäumer K; Schmid R; Pfluger T; Hahn K
Eur J Nucl Med Mol Imaging; 2003 Jul; 30(7):995-1003. PubMed ID: 12739070
[TBL] [Abstract][Full Text] [Related]
18. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
[TBL] [Abstract][Full Text] [Related]
19. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM
J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702
[TBL] [Abstract][Full Text] [Related]
20. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer.
Sung J; Espiritu JI; Segall GM; Terris MK
BJU Int; 2003 Jul; 92(1):24-7. PubMed ID: 12823377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
